Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1) (MACS0977)
This study is currently recruiting participants.
Verified February 2013 by Novartis
Study NCT01365468   Information provided by Novartis

First Received on May 27, 2011.   Last Updated on February 21, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Neurofibroma
Neurofibroma, Plexiform
Neurofibromatoses
Neurofibromatosis 1
Osteitis Fibrosa Cystica
More general conditions related to this trial
Bone Diseases
Bone Diseases, Endocrine
Genetic Diseases, Inborn
Heredodegenerative Disorders, Nervous System
Musculoskeletal Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Neoplastic Syndromes, Hereditary
Nerve Sheath Neoplasms
Nervous System Diseases
Nervous System Neoplasms
Neurocutaneous Syndromes
Neurodegenerative Diseases
Neuromuscular Diseases
Peripheral Nervous System Diseases
Peripheral Nervous System Neoplasms
Interventions listed in this trial
Everolimus
Additional drug interventions recognized in this trial
Sirolimus
More general drug interventions related to this trial
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antineoplastic Agents
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Novartis Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services